Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Data from a Nationwide Belgian Registry

被引：3

作者：

Devos, Timothy ^{[1
,2
]}

Havelange, Violaine ^{[3
]}

Theunissen, Koen ^{[4
]}

Meers, Stef ^{[5
]}

Benghiat, Fleur Samantha ^{[6
]}

Gadisseur, Alain ^{[7
]}

Vanstraelen, Gaetan ^{[8
]}

Andre, Marc ^{[9
]}

Bailly, Benjamin ^{[10
]}

Granacher, Nikki ^{[11
]}

Lewalle, Philippe ^{[12
]}

De Becker, Ann ^{[13
]}

Van Eygen, Koen ^{[14
]}

Lejeune, Marie ^{[15
]}

Deeren, Dries ^{[16
]}

Nifosi, Gianfilippo ^{[17
]}

Triffet, Agnes ^{[18
]}

Vrelust, Inge ^{[19
]}

Bekaert, Julie ^{[20
]}

Beck, Michael ^{[21
]}

Selleslag, Dominik ^{[22
]}

机构：

[1] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[2] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Expt Transplantat, Leuven, Belgium

[3] Clin Univ St Luc, Brussels, Belgium

[4] Jessa Ziekenhuis, Hasselt, Belgium

[5] Algemeen Ziekenhuis Klina, Brasschaat, Belgium

[6] Hop Erasme, Brussels, Belgium

[7] Univ Hosp Antwerp, Edegem, Belgium

[8] Ctr Hosp Pelzer Tourelle, Verviers, Belgium

[9] CHU UCL Namur Site Godinne, Dept Hematol, Yvoir, Belgium

[10] Hop Jolimont, Haine St Paul, Belgium

[11] Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium

[12] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[13] Univ Ziekenhuis Brussel, Jette, Belgium

[14] Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium

[15] Ctr Hosp Univ Liege Sart Tilman, Liege, Belgium

[16] Algemeen Ziekenhuis Delta, Roeselare, Belgium

[17] Ctr Hosp Univ Brugmann, Brussels, Belgium

[18] Ctr Hosp Univ Charleroi Vesale, Charleroi, Belgium

[19] Algemeen Ziekenhuis Sint Elisabeth, Turnhout, Belgium

[20] Incyte Biosci Int Sarl, Lausanne, Switzerland

[21] Incyte Biosci Benelux BV, Amsterdam, Netherlands

[22] Algemeen Ziekenhuis Sint Jan Brugge, Brugge, Belgium

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-127923

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4161

引用

页数：4

共 50 条

[1] PONATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Narayanan, V.
Pollyea, D. A.
Gutman, J. A.
Jimeno, A.
DRUGS OF TODAY, 2013, 49 (04) : 261 - 269
[2] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
Hijiya, Nobuko
Zwaan, C. Michel
Rizzari, Carmelo
Foa, Roberto
Abbink, Floor
Lancaster, Donna
Landman-Parker, Judith
Millot, Frederic
Moppett, John
Nelken, Brigitte
Ducassou, Stephane
Putti, Maria Caterina
Tian, Xianbin
Sinclair, Karen
Santanastasio, Helene
Buchbinder, Aby
Kearns, Pamela
PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
[3] The OMNI Patient Registry: A Prospective, Observational, Non-Interventional Registry to Evaluate Vascular Safety of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Stemhagen, Annette
Adib, Deyaa
Lustgarten, Stephanie
McGarry, Lisa
du Moulin, Ruth
Santillana, Sergio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S309 - S310
[4] Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
Pavlovsky, Carolina
Chan, Onyee
Talati, Chetasi
Pinilla-Ibarz, Javier
FUTURE ONCOLOGY, 2019, 15 (03) : 257 - 269
[5] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
Dai, Guowei
Roy, Amit
Mandava, Mohan
Blackwood-Chirchir, Anne
Luo, Roger
Wu, Chiyuan
Pfister, Marc
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
[6] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Jabbour, Elias
Koller, Paul B.
Oehler, Vivian G.
Jamy, Omer H.
Mukherjee, Sudipto
Hunter, Anthony M.
Baer, Maria R.
Beck, Joseph T.
Chen, Zi
Guo, Huanshan
Fu, Lei
Men, Lichuang
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Kantarjian, Hagop
Jiang, Lixin
Wang, Cunlin
BLOOD, 2022, 140
[7] Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Shamroe, Caitlin L.
Comeau, Jill M.
ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1540 - 1546
[8] Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Anagnostou, Theodora
Litzow, Mark R.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2018, 8 : 1 - 9
[9] SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS
Saglio, G.
le Coutre, P.
Cortes, J.
Mayer, J.
Rowlings, P.
Subar, M.
Preston, J.
Shah, N.
HAEMATOLOGICA, 2014, 99 : 329 - 329
[10] Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
Tobon, Katherine
Consalvo, Kylie
Kareem, Syeda Saba
Lancet, Jeffrey E.
Komrokji, Rami S.
Pinilla-Ibarz, Javier
Sallman, David
Eatrides, Jennifer
Walker, Alison R.
Chavez, Julio C.
Isenalumhe, Leidy Lismeris
Shah, Bijal
BLOOD, 2024, 144 : 2821 - 2821

← 1 2 3 4 5 →